Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Songsong Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and …. Hauptthemen laut MEDLINE: Glioblastoma, Cancer Vaccines, Vaccination, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Tumor vaccines have shown great promise for treating various malignancies; however, glioblastoma (GBM), characterized by its immunosuppressive tumor microenvironment, high heterogeneity, and limited accessibility, has achieved only modest clinical benefits. Here, it is reported that GBM cell lysate nanovaccines boosted with TLR9 agonist CpG ODN (GlioVac) via a strategic vaccination regimen achieve complete regression of malignant murine GBM tumors. Subcutaneous administration of GlioVac promotes uptake by cervical lymph nodes and antigen presentation cells, bolstering antigen cross‐presentation and infiltration of GBM‐specific CD8 + T cells into the tumor. Notably, a regimen involving two subcutaneous and three intravenous vaccinations not only activates systemic anti‐GBM immunity but also further enhances the tumor infiltration of cytotoxic T lymphocytes, effectively reshaping the “cold” GBM tumor into a “hot” tumor. This approach led to a state of tumor‐free survival in 5 out of 7 mice bearing the established GL261 GBM model with complete protection from tumor rechallenge. In an orthotopic hRas‐GBM model induced by a lentiviral plasmid, GlioVac resulted in ≈100% complete tumor regression. These findings suggest that GlioVac provides a personalized therapeutic vaccine strategy for glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, P. R. China.
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, P. R. China.
ORCID-Profile: Zhiyuan Zhong
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Zhao, S., Qu, Y., Sun, Z., Zhang, S., Xia, M., Shi, Y., Wang, J., Wang, Y., Zhong, Z., & Meng, F. (2025). Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500911
Vancouver
Zhao S, Qu Y, Sun Z, Zhang S, Xia M, Shi Y, et al. Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500911
BibTeX
@article{Zhao2025,
author = {Zhao, Songsong and Qu, Yanyi and Sun, Zhiwei and Zhang, Shuo and Xia, Mingyu and Shi, Yan and Wang, Jingyi and Wang, Yuan and Zhong, Zhiyuan and Meng, Fenghua},
title = {Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500911}
}
EUVIMED